Sun Pharma Advanced Research Company Ltd

SPARC Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sun Pharma Advanced Research Company Ltd

₹ 204 7.44%
22 Nov - close price
sparc.life BSE: 532872 NSE: SPARC
About

Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.[1]

Key Points

Leadership[1]
First listed pharma R&D company out of India where founders still own 70% and continue to invest.

Website BSE NSE
  • Market Cap ₹ 6,636 Cr.
  • Current Price ₹ 204
  • High / Low ₹ 474 / 189
  • Stock P/E
  • Book Value ₹ 3.87
  • Dividend Yield 0.00 %
  • ROCE -108 %
  • ROE -121 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Stock is trading at 52.8 times its book value
  • Company has low interest coverage ratio.
  • Company might be capitalizing the interest cost
  • Promoters have pledged 69.5% of their holding.
  • Debtor days have increased from 62.5 to 75.0 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Miscellaneous

Part of BSE 400 MidSmallCap Index BSE 250 SmallCap Index BSE Allcap BSE Healthcare BSE 500

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
48 24 21 14 17 17 13
137 126 113 116 122 110 116
Operating Profit -90 -102 -91 -103 -106 -93 -103
OPM % -188% -427% -432% -740% -639% -555% -800%
11 10 8 6 4 2 0
Interest 0 0 0 0 1 1 1
Depreciation 3 3 3 3 3 3 3
Profit before tax -82 -95 -86 -100 -105 -96 -107
Tax % 0% 0% 0% 0% 0% 0% 0%
-82 -95 -86 -100 -106 -96 -107
EPS in Rs -2.53 -2.94 -2.66 -3.07 -3.26 -2.96 -3.31
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 TTM
239 76 60
453 478 465
Operating Profit -214 -402 -405
OPM % -90% -532% -674%
11 29 12
Interest 8 2 3
Depreciation 12 13 13
Profit before tax -223 -387 -408
Tax % 0% 0%
-223 -387 -409
EPS in Rs -6.86 -11.93 -12.60
Dividend Payout % 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -68%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -74%
Stock Price CAGR
10 Years: 1%
5 Years: 4%
3 Years: -7%
1 Year: -25%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: -121%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024
Equity Capital 32 32
Reserves 480 93
16 61
302 328
Total Liabilities 830 515
106 108
CWIP 27 44
Investments 291 2
406 362
Total Assets 830 515

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024
-69 -429
-548 392
617 42
Net Cash Flow -1 5

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024
Debtor Days 50 75
Inventory Days
Days Payable
Cash Conversion Cycle 50 75
Working Capital Days -189 -494
ROCE % -108%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
68.10% 69.09% 69.09% 69.09% 68.23% 65.68% 65.68% 65.68% 65.68% 65.68% 65.68% 65.68%
2.51% 2.38% 2.40% 2.38% 3.48% 3.64% 3.64% 3.67% 3.30% 3.24% 2.64% 2.15%
0.55% 0.76% 0.76% 0.76% 0.76% 0.63% 0.63% 0.65% 0.67% 0.67% 0.17% 0.21%
28.84% 27.77% 27.75% 27.77% 27.53% 30.04% 30.06% 29.99% 30.36% 30.41% 31.51% 31.96%
No. of Shareholders 95,03992,73694,49493,71896,33798,7771,00,8071,01,4331,03,9901,02,7431,25,1841,28,205

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls